Alexandria Hammond
Stock Analyst at B of A Securities
(3.39)
# 947
Out of 5,064 analysts
16
Total ratings
70%
Success rate
13.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Upgrades: Neutral | $266 → $445 | $547.96 | -18.79% | 2 | Nov 3, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $63 → $64 | $54.31 | +17.84% | 4 | May 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $755.90 | +52.14% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $25.04 | -0.16% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $23.72 | +68.63% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $97.76 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $1,059.70 | -5.63% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $203.90 | -6.82% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $126.64 | -13.14% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $46.25 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $175.30 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $236.28 | -13.24% | 1 | Nov 15, 2024 |
Madrigal Pharmaceuticals
Nov 3, 2025
Upgrades: Neutral
Price Target: $266 → $445
Current: $547.96
Upside: -18.79%
Akero Therapeutics
May 27, 2025
Maintains: Buy
Price Target: $63 → $64
Current: $54.31
Upside: +17.84%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $755.90
Upside: +52.14%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $25.04
Upside: -0.16%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $23.72
Upside: +68.63%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $97.76
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $1,059.70
Upside: -5.63%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $203.90
Upside: -6.82%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $126.64
Upside: -13.14%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $46.25
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $175.30
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $236.28
Upside: -13.24%